<?xml version="1.0"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="Optica Fall Vision Meeting Abstract">
	<front>
		<journal-meta>
			<journal-id journal-id-type="hwp">jov</journal-id>
			<journal-id journal-id-type="publisher-id">JOVI</journal-id>
			<journal-title-group>
				<journal-title>Journal of Vision</journal-title>
			</journal-title-group>
			<issn pub-type="epub">1534-7362</issn>
			<publisher>
				<publisher-name>Association for Research in Vision and Ophthalmology</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="doi">10.1167/jov.23.11.6</article-id>
			<article-id pub-id-type="manuscript">Talks_6</article-id>
			<article-categories>
				<subj-group subj-group-type="category">
					<subject>Invited Session I: Vision restoration</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Invited Session I: Vision restoration: Genetic therapies for inherited retinal disorders</article-title>
			</title-group>
			<contrib-group>
                          
				<contrib contrib-type="author">
					<name>
						<surname>Huckfeldt</surname>
						<given-names>Rachel</given-names>
					</name>
                                        
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>


				</contrib>




                          
				<aff id="aff1">
					<label><sup>1</sup></label>
					<institution>Massachusetts Eye and Ear</institution>
				</aff>


			</contrib-group>
			<pub-date pub-type="ppub"><month>9</month>
				<year>2023</year>
			</pub-date>
			<pub-date pub-type="epub"><month>9</month>
				<year>2023</year>
			</pub-date>
						<volume>23</volume>
						<issue>11</issue>
						<fpage>6</fpage>
						<lpage>6</lpage>
			<permissions>
				<license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
					<license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</license-p>
				</license>
			</permissions>
			<abstract>
				<p>The accessibility of the retina makes it an attractive target for genetic therapies to treat inherited retinal disorders (IRDs). The FDAâ€™s approval of voretigene neparvovec-rzyl in 2017 for biallelic RPE65-associated retinal dystrophies demonstrated that the safety and efficacy needed for regulatory approval of such therapies could be achieved. Clinical trials assessing a growing array of genetic strategies are offering valuable insight on the potential of these therapies for the treatment of IRDs while also emphasizing ongoing challenges in their development. This presentation will review the range of genetic therapies for IRDs being tested in clinical trials and the results to-date as well as discuss challenges including those related to evaluating efficacy. 
</p>
			</abstract>
		</article-meta>
	</front>
	<back>
                
               <fn-group>
			<fn>
				<p>Funding: Funding: None</p>
			</fn>
		</fn-group>

	</back>
</article>